<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Jacobson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cytomegalovirus (CMV) retinitis is the most common serious ocular complication of acquired immunodeficiency syndrome (AIDS). The majority of disease is related to reactivation of latent infection. However, the introduction of potent combination antiretroviral therapy (ART) regimens in 1996 has led to changes in the incidence, natural history, management, and sequelae of CMV retinitis [<a href="#rid1">1</a>].</p><p>The clinical manifestations, pathogenesis, risk factors, and diagnosis of CMV retinitis are discussed here. The treatment of CMV retinitis and the use of antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis"</a> and  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CMV IN THE ERA OF POTENT COMBINATION ART</span><span class="headingEndMark"> — </span>CMV retinitis was first reported as a complication of AIDS in 1982. Prior to the availability of potent combination antiretroviral therapy (ART) in 1996, CMV retinitis occurred in 21 to 44 percent of patients with AIDS, primarily in those with a CD4 T lymphocyte count below 50 cells/microL [<a href="#rid2">2-4</a>]. In early case series, patients who survived beyond six months without CMV-specific treatment became severely visually impaired or blind. The median time to progression of disease into previously uninvolved areas of the retina while on CMV-specific antiviral therapy was 47 to 104 days, mean survival after diagnosis was 6 to 10 months, and indefinite maintenance therapy was essential [<a href="#rid1">1</a>].</p><p>However, the introduction of potent combination ART has had a dramatic impact on CMV disease in the patient with HIV. CMV disease essentially occurs only in patients with advanced immunosuppression, such as those who are either not receiving or have failed to respond to ART [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>In the era prior to the availability of potent ART regimens, the incidence of CMV retinitis was high. As an example, in one observational study, approximately 25 percent of AIDS patients with a CD4 count &lt;200 cells/microL developed CMV retinitis during four years of follow-up [<a href="#rid6">6</a>]. In addition, in the placebo arm of a clinical trial of oral <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> prophylaxis, which enrolled AIDS patients with a CD4 count of &lt;50 cells/microL or patients with a history of an AIDS-defining opportunistic infection and a CD4 count &lt;100 cells/microL, the incidence of CMV retinitis was 24 percent after only 12 months of follow-up [<a href="#rid7">7</a>]. </p><p>However, the incidence of CMV retinitis has decreased by 80 percent or more since modern ART regimens became available and survival after diagnosis has increased [<a href="#rid1">1,8</a>]. This trend has been described in the United States and Europe [<a href="#rid9">9,10</a>]. In an observational study was performed of 1600 AIDS patients who were seen every six months for ophthalmic examination from 1996 to 2009 [<a href="#rid10">10</a>]. The incidence rate of CMV retinitis was 0.36/100 person-years based upon 29 incident cases during 8134 person-years of follow-up [<a href="#rid10">10</a>]. The four-year incidence rate of CMV retinitis was 12 percent, a 52 percent reduction compared with historical data [<a href="#rid6">6</a>]. A more dramatic reduction in the incidence of CMV retinitis was observed by the San Francisco Department of Public Health’s active surveillance program. From 1996 to 2000 and 2001 to 2008, the incidence of CMV retinitis after an initial AIDS diagnosis decreased by 94 percent [<a href="#rid11">11</a>]. </p><p>In addition to a decrease in incidence, CMV retinitis now appears to make up a smaller proportion of CMV end-organ disease cases. In a cohort of 206 ART-naïve HIV patients presenting for care with a CD4 count ≤100 cells/mcgl between 2004 and 2013 and enrolled in a prospective National Institutes for Health observational study, only 7 (28 percent) of those ultimately diagnosed with CMV end-organ disease had evidence of retinitis on ophthalmologic exam, while 17 (68 percent) had histologically confirmed CMV gastrointestinal disease occur [<a href="#rid12">12</a>]. In contrast, 100 percent of the 39 enrollees in the placebo arm of the clinical trial of oral <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> prophylaxis described above, which was conducted before potent ART regimens were widely available, had evidence of retinitis on ophthalmologic exam, while only 6 (15 percent) had histologically confirmed CMV gastrointestinal disease [<a href="#rid7">7</a>]. This phenomenon may be due to the decreased incidence of CMV viremia with widespread use of ART, in turn leading to decreased incidence of CMV spread (eg, retinitis) resulting from hematogenous spread. In contrast, gastrointestinal CMV likely arises from direct infection of gut epithelial cells resulting from local CMV reactivation in sites such as the salivary glands, which occurs frequently in immunocompetent people [<a href="#rid13">13</a>]. Thus, immune reconstitution by ART may have less impact on reducing the incidence of CMV gastrointestinal disease than retinitis.</p><p>CMV retinitis continues to be a cause of blindness among patients with AIDS in low- and middle-income countries [<a href="#rid14">14-18</a>]. However, with increased availability of ART over the past decade, the prevalence of this disease has fallen [<a href="#rid19">19</a>]. Studies from Africa and Southeast Asia report a prevalence of 5.4 and 10.1 percent, respectively, among patients with CD4 counts &lt;100 cells/microL [<a href="#rid18">18,20</a>]. In another report from Mozambique, CMV retinitis prevalence was 9.7 percent; six of the eight patients with active disease were failing ART, suggesting that CMV retinitis should be suspected in patients failing ART as well as in ART-naïve patients with low CD4 counts [<a href="#rid21">21</a>]. Lack of diagnostic capacity continues to be the central problem in management of this disease, with still no cases reported in the literature in several sub-Saharan countries, such as Kenya, Zambia, Zimbabwe, Eswatini, and Lesotho, all of which have &gt;5 percent HIV prevalence among young adults. </p><p class="headingAnchor" id="H4"><span class="h2">Effect on clinical presentation</span><span class="headingEndMark"> — </span>The initiation of ART with associated immune reconstitution may also lead to different clinical presentations of symptomatic CMV disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients may present with CMV retinitis in the setting of higher CD4 counts (&gt;100 cells/microL) secondary to early immunologic recovery of T-cells after initiation of ART [<a href="#rid22">22</a>]. This emphasizes the fact that early immune reconstitution is "incomplete" and the patient is still at risk for opportunistic infections early during treatment [<a href="#rid23">23</a>]. Thus, clinicians should not eliminate the possibility of CMV retinitis simply based on a relatively high CD4 count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients who have quiescent CMV retinitis (or subclinical CMV retinal infection) at the time potent antiretroviral therapy is initiated, subsequently develop new areas of retinal opacification within the first months after responding to antiretroviral treatment with a rise in their absolute CD4+ T cell counts [<a href="#rid22">22</a>]. These new retinal lesions are either located on the border of previous healed lesions or may be the initial clinical presentation of CMV retinitis. In patients already on maintenance anti-CMV therapy, this new retinal opacification does not signify a failure of the anti-CMV therapy or antiretroviral therapy, and the lesions subsequently heal with continuation of the same anti-CMV regimen.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Morbidity and mortality</span><span class="headingEndMark"> — </span>The introduction of potent ART was also associated with decreased morbidity and mortality related to ocular involvement, slower rates of retinal progression, ocular complications, and improved survival after diagnosis [<a href="#rid24">24-26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In the era before potent combination ART, the rates of visual loss in eyes were substantial. The two major causes were retinitis, involving either the macula or the optic nerve, and retinal detachment. In the modern ART era, visual outcomes improved significantly [<a href="#rid27">27</a>], and the overall rate of progression of retinitis is significantly slower than before [<a href="#rid28">28</a>]. However, patients with CMV retinitis who initiate ART are at risk of developing an ocular inflammatory syndrome, termed immune recovery uveitis, which can cause substantial vision loss [<a href="#rid29">29</a>]. (See <a class="local">'CMV immune recovery uveitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of ART has also been associated with a decreased incidence of CMV retinitis in the uninvolved second eye [<a href="#rid30">30</a>]. In a study of 376 consecutive patients with AIDS and unilateral CMV retinitis, subjects were followed for the development of second-eye retinitis. The use of ART was associated with a 46 percent reduction in incidence of retinitis in the uninvolved eye compared to untreated patients. Rates of retinal detachment have also been reduced compared to historical controls [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large observational cohort of 1583 AIDS patients who were enrolled between 1998 and 2003, mortality rates among patients with a baseline CD4 count &gt;100 cells/microL were similar in those with or without a history of CMV retinitis [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">CMV specific immune responses</span><span class="headingEndMark"> — </span>Although ART clearly leads to restoration of immune protection against further progression of CMV retinitis in nearly all CMV retinitis patients who respond to potent antiretroviral therapy [<a href="#rid24">24,33,34</a>], it is not clear whether ART leads to complete restoration of CMV-specific CD4+ and CD8+ T cell responses [<a href="#rid35">35-38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>As an example, in one longitudinal study of a CMV-specific CD8+ interferon gamma cytokine flow cytometry assay, immune responses in 10 patients with active CMV retinitis were compared to 20 patients who had a history of CMV retinitis and who successfully discontinued maintenance therapy [<a href="#rid35">35</a>]. CD8+ T cell responses were demonstrated in only 3 of 10 patients with active CMV retinitis compared to all 20 patients with a past history of CMV, suggesting full restoration of this critical CMV-specific T cell response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 87 patients with CD4 T counts less than 50 cells, positive baseline CMV-specific interferon gamma responses identified by ELISPOT (enzyme-linked immunospot) assay, were associated with delayed development of CMV viremia, end-organ disease, and death [<a href="#rid36">36</a>]. Factors associated with positive ELISPOT results were higher CD4 T cell counts, lower HIV ribonucleic acid (RNA) levels, and longer duration of ART. However, reconstitution of CMV-specific CD4+ and CD8+ T cell responses (as measured by flow cytometry) were not observed during the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study identified three CMV-specific T cell parameters that discriminated between patients with active CMV retinitis and those who had full clinical recovery [<a href="#rid39">39</a>]. However, when these parameters were examined in a large, longitudinal study, they were not useful in predicting risk of developing CMV retinitis in patients with AIDS, possibly because the interval between the decrease in critical CMV-specific T cell subsets and the onset of retinitis was very short [<a href="#rid40">40</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Many studies support the hypothesis that CMV retinitis results from hematogenous spread of CMV to the eye. Studies in transplant recipients and patients with AIDS indicate that CD4-dependent cytotoxic T lymphocyte activity of CMV antigen-specific CD8+ T cells is critical for preventing CMV replication and end-organ disease, and that impaired CD4 cell function or number is the key immune deficit that permits uncontrolled CMV replication [<a href="#rid35">35,41,42</a>].</p><p>Although most cases of CMV retinitis occur in patients with a CD4 count &lt;50 cells/microL, patients may be predisposed before such severe CD4 cell depletion as illustrated below:</p><p class="bulletIndent1"><span class="glyph">●</span>In a longitudinal, prospective study, patients with AIDS who subsequently developed CMV retinitis had lower T-cell proliferative responses (in an assay that primarily measured CD4+ T cell proliferation) to CMV both early and late in disease, compared to patients who did not develop retinitis [<a href="#rid43">43</a>]. Genetic factors may contribute to this predisposition since low responses to CMV were more common in those with HLA B44 and DR7.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A longitudinal study analyzed the dynamics of CMV-specific CD8+ and CD4+ T cell responses in parallel with CMV deoxyribonucleic acid (DNA) in 19 patients with HIV, 10 of whom had progression to CMV end-organ disease [<a href="#rid44">44</a>]. In individuals progressing to end-organ disease, CMV-specific IFN-gamma producing CD4+ T cells disappeared during the year before onset of clinical disease. This decline was accompanied by a sharp increase in CMV DNA before symptom onset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is also evidence that higher proportions of regulatory T cells and of CMV-specific T-cell responses, which are characteristic of regulatory T cells, are associated with an increased risk of AIDS-related CMV end-organ disease [<a href="#rid45">45</a>].</p><p></p><p>In addition, there may be other genetic predispositions to developing CMV retinitis. For example, CMV contains a human interleukin-10 (IL-10) homolog in its genome to evade host immune reactions. Variants of the human IL-10 receptor may influence susceptibility to developing CMV retinitis in patients with AIDS [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H8"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>CMV retinitis is characterized histologically by full-thickness retinal necrosis and edema that is subsequently replaced by thin, atrophic scar tissue. This scar tissue is susceptible to tearing, which can lead to subsequent retinal detachment [<a href="#rid47">47</a>]. Without antiviral treatment or immune reconstitution, the retinal lesions enlarge centrifugally. The portions of the retina destroyed by CMV do not regenerate functionally. Thus, the goal of therapy for CMV retinitis is to prevent further retinal necrosis and loss of vision.</p><p class="headingAnchor" id="H9"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H10"><span class="h2">CMV viremia</span><span class="headingEndMark"> — </span>The presence of CMV virus in blood (as measured by culture, CMV DNA amplification, or antigen detection) has been studied as a risk factor for the development of CMV retinitis in patients with AIDS with varying results.</p><p>Several studies initiated before 1996 suggested a close association between CMV viremia and risk of CMV disease and mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>One early study demonstrated that CMV DNA load was an independent marker of CMV disease and survival and was more predictive than HIV-1 RNA [<a href="#rid48">48</a>]. In addition, patients who attained CMV viral suppression with pre-emptive oral <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> therapy had a significantly lower risk of developing CMV disease and higher rates of survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large study of 619 AIDS patients, a positive plasma CMV DNA PCR was associated with a 2.5-fold increased risk of death [<a href="#rid49">49</a>]. Furthermore, each log(10) increase in baseline CMV DNA load was associated with a threefold increase in CMV disease and a twofold increase in mortality. However, 14 percent of individuals without detectable plasma CMV DNA at entry developed CMV end-organ disease as well.</p><p></p><p>However, the rate of CMV end-organ disease is lower in patients receiving combination ART. As an example, a randomized, placebo-controlled trial was performed in 338 patients with advanced AIDS, most of whom were taking ART [<a href="#rid50">50</a>]. Patients had serial measurements of CMV DNA by PCR and indirect ophthalmoscopy every eight weeks. Those with onset of CMV viremia were randomly assigned to either induction or maintenance doses of <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> or placebo. The following results were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Sixty-eight (20 percent) developed viremia, of whom 47 entered the treatment phase of the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no significant difference in rates of CMV end-organ disease or death between treatment arms.</p><p></p><p>In addition to the lack of benefit of pre-emptive anti-CMV therapy, this study highlights the much lower prevalence of CMV disease in patients taking modern ART regimens, compared to rates of 50 percent that were previously documented. </p><p class="headingAnchor" id="H13"><span class="h2">Iatrogenic risk factors</span><span class="headingEndMark"> — </span>Iatrogenic risk factors (corticosteroids use, chemotherapy, radiotherapy and blood transfusions) for CMV retinitis were evaluated in a case-control study of 120 patients with CMV retinitis and 159 control patients, all of whom had AIDS and a CD4 T-cell &lt;50 cells/microL [<a href="#rid51">51</a>]. Among the risk factors studied, only corticosteroid use was predictive of CMV retinitis (odds ratio 6.41, 95 percent CI 2.35-17.51).</p><p class="headingAnchor" id="H14"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>CMV retinitis can cause blurring or loss of central vision, scotomata ("blind spots"), floaters, or photopsia ("flashing lights"), depending upon the anatomic site of retinal destruction and whether or not retinal detachment has occurred [<a href="#rid47">47</a>]. A complaint of floaters or photopsia is the single most powerful symptomatic predictor of CMV retinitis in an AIDS patient [<a href="#rid52">52</a>] and should always be evaluated with dilated ophthalmoscopy. Lesions close to or involving the fovea or optic nerve are particularly likely to cause serious visual impairment. Acute loss of vision can occur if retinitis leads to retinal detachment.</p><p>CMV retinitis usually occurs as unilateral disease, but in the absence of therapy, involvement of the contralateral eye will often occur.</p><p class="headingAnchor" id="H15"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Retinal detachment is one of the major causes of vision loss in patients with CMV retinitis. Although the retina can be reattached anatomically by surgery, postoperative visual acuity is almost never as good as it was before detachment occurred. Peripheral (ie, anterior) retinal lesions underlie the vitreous base, where the vitreous body is normally adherent to the retina. Thus, large peripheral lesions are associated with an increased risk of retinal detachment.</p><p>In addition, some patients experiencing the immune reconstitution syndrome have developed a number of other ocular complications, including anterior uveitis, vitritis, and cystoid macular edema [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a> and <a class="local">'CMV immune recovery uveitis'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>CMV retinitis is generally diagnosed by an experienced ophthalmologist on the basis of characteristic retinal changes [<a href="#rid53">53</a>]. Indirect ophthalmoscopy reveals yellow-white retinal lesions with indistinct margins, sometimes with a granular appearance, often located close to retinal vessels and associated with hemorrhage. In the absence of antiretroviral therapy, CMV retinitis is associated with little inflammation of the vitreous; retinitis invariably progresses without treatment, usually within 10 to 21 days after presentation [<a href="#rid53">53</a>]. In resource-limited settings, ophthalmologists may be relatively inaccessible, and point-of-care indirect ophthalmoscopy by a trained nonophthalmologist may increase detection of retinitis up to 10-fold [<a href="#rid20">20</a>].</p><p>Lesions can be described as "fulminant and edematous" versus "indolent and granular" based on several factors, including the degree of retinal opacity (whitening), retinal hemorrhage, and lesion shape and location [<a href="#rid54">54</a>]. One retrospective observational study of 100 AIDS patients with untreated CMV retinitis suggested that lesion opacity may be a surrogate of disease severity [<a href="#rid54">54</a>]. The intensity of the white opaque borders is thought to represent virus activity [<a href="#rid55">55</a>].</p><p>Careful ophthalmologic exam is also important in distinguishing CMV retinitis from other retinal lesions: </p><p class="bulletIndent1"><span class="glyph">●</span>Small lesions may be difficult to differentiate from benign cotton wool spots; as a result, serial funduscopic examinations are sometimes required to make the diagnosis. The rate of enlargement of CMV lesions toward the fovea is slow but gradual. It is therefore safe to perform frequent examinations to confirm uncertain diagnoses before initiating therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV retinitis should be distinguished from progressive ocular retinal necrosis (PORN), a more aggressive retinitis typically caused by varicella zoster virus (VZV), or less commonly herpes simplex virus (HSV), which occurs primarily in patients with advanced HIV (CD4 &lt;100 cells/microL). Very rarely, CMV has been implicated in PORN [<a href="#rid56">56,57</a>], and cases of PORN have occurred in patients without HIV [<a href="#rid58">58,59</a>]. PORN initially presents with multifocal, necrotizing lesions in the peripheral retina and progresses more rapidly compared with CMV retinitis [<a href="#rid60">60</a>]. In contrast to CMV retinitis, which typically involves the retinal vasculature, PORN typically spares retinal vessels. PORN lesions often rapidly coalesce, cause full thickness retinal necrosis, and lead to retinal detachment. For cases in which the clinical differentiation between CMV retinitis and PORN is not obvious, an aqueous or vitreous sample submitted for CMV, VZV, and HSV polymerase chain reaction (PCR) can be helpful for clarifying the diagnosis [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical syndrome of immune recovery uveitis may present with similar symptoms as the initial episode of CMV retinitis, but can be distinguished by a full ophthalmologic examination. (See <a class="local">'CMV immune recovery uveitis'</a> below.)</p><p></p><p>CMV viremia detected by PCR, antigen assays, or blood culture are <strong>not</strong> used to make a diagnosis of CMV retinitis or any other CMV end-organ disease in patients with HIV given the poor sensitivity and specificity of these tests for determining end-organ disease. As an example, in a study of patients with advanced AIDS and CMV viremia detected by PCR, fewer than 50 percent developed CMV end-organ disease at one year despite receiving no anti-CMV therapy [<a href="#rid49">49</a>]. Conversely, using the above methods for viral detection, CMV viremia is detected in less than half of patients with active retinitis [<a href="#rid62">62,63</a>].</p><p>Similarly, the presence of CMV antibodies is typically not useful in diagnosing CMV retinitis [<a href="#rid53">53</a>]. A negative IgG CMV antibody indicates that CMV is unlikely to be the etiology of retinitis. However, on rare occasion a patient with advanced HIV and prior CMV infection may serorevert from antibody-positive to antibody-negative. Thus, a negative CMV IgG antibody significantly lowers the diagnostic possibility of CMV, but does not completely eliminate it from consideration.</p><p class="headingAnchor" id="H17"><span class="h1">CMV IMMUNE RECOVERY UVEITIS</span><span class="headingEndMark"> — </span>After an initial period of treatment with anti-CMV therapy and antiretroviral therapy (ART), patients may develop significant intraocular inflammation secondary to immune recovery. This entity is known as immune recovery uveitis (IRU) and can lead to significant ocular morbidity [<a href="#rid1">1,29,33,64-66</a>]. Complications of IRU accounted for approximately 50 percent of incident vision loss among patients with longstanding CMV retinitis and immune recovery in a study published in 2006 [<a href="#rid67">67</a>]. Anecdotally, IRU has rarely been diagnosed over the last decade.</p><p>Uveitis is a general term that refers to inflammation in the eye; vitritis refers to inflammation within the vitreous cavity and is a subset of uveitis. Immune recovery uveitis is associated with vitreous inflammation with or without cystoid macular edema, epiretinal membrane, or retinal neovascularization in patients with ART-mediated immune recovery and inactive CMV retinitis [<a href="#rid1">1,68-70</a>]. Although some patients develop transient vitritis soon after initiating ART and quickly recover normal visual function, IRU that leads to macular edema can often be associated with a significant decline in visual acuity despite successful treatment of CMV retinitis [<a href="#rid29">29,70-72</a>].</p><p>The pathogenesis of IRU is not well understood, but may be related to T cell-mediated immune reconstitution to latent CMV intraocular antigens [<a href="#rid33">33,64,70,73</a>] (see  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>). Symptoms include floaters, blurred vision, or photophobia. Patients may also develop other inflammatory complications such as cataract, glaucoma, and vitreous hemorrhage; neovascularization can occur as a late complication [<a href="#rid64">64,69,74,75</a>]. In a study of 54 patients with CMV retinitis conducted early in the modern ART era, the onset of IRU occurred within 2 to 84 weeks (median 20 weeks) after an improvement of CD4 cell counts [<a href="#rid65">65</a>].</p><p>In a subsequent study of 374 patients with AIDS and CMV retinitis affecting 539 eyes, 36 patients (9.6 percent) developed IRU involving 50 eyes [<a href="#rid29">29</a>]. Risk factors included prior CMV involvement of greater than 25 percent of the retina, involvement of the posterior pole of the eye, or treatment with intravitreal <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>. No patient with IRU was observed to have active retinitis or detectable CMV DNA in peripheral blood. The extent of prior CMV retinitis and the use of either systemic or intravitreal cidofovir has been identified as a potential cofactor in IRU in other studies as well [<a href="#rid65">65,70,76,77</a>].</p><p>Any patient with a history of immune recovery, quiescent CMV retinitis, and new visual symptoms, should be referred promptly for ophthalmic examination to evaluate for CMV progression, relapse, or immune recovery uveitis. On ophthalmologic examination, IRU is characterized by inflammation in the anterior chamber and vitreous cavity, which is best diagnosed with a combination of slit lamp examination and indirect ophthalmoscopy.</p><p>The treatment of IRU is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis", section on 'CMV immune reconstitution inflammatory syndromes'</a>.)</p><p class="headingAnchor" id="H2802415710"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus (CMV) retinitis is the most common serious ocular complication of AIDS. Most disease is related to reactivation of latent infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for CMV retinitis include a CD4 count &lt;50 cells/microL, history of prior opportunistic infection, high HIV RNA level, and CMV viremia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The introduction of potent combination antiretroviral therapy (ART) regimens has been associated with a decreased incidence of CMV retinitis, lower rates of ocular complications, and improved survival after diagnosis. (See <a class="local">'CMV in the era of potent combination ART'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV retinitis can cause blurring or loss of central vision, scotomata ("blind spots"), floaters, or photopsia ("flashing lights"). Complications include retinal detachment with complete visual loss. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV retinitis is generally diagnosed by an experienced ophthalmologist based on characteristic retinal changes. Indirect ophthalmoscopy reveals yellow-white retinal lesions with indistinct margins, sometimes with a granular appearance, often located close to retinal vessels and associated with hemorrhage. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for CMV viremia by DNA PCR, blood antigen, or blood culture is not helpful diagnostically. These assays have poor sensitivity and specificity for determining CMV end-organ disease and should not be used in clinical decision making when patients with AIDS are suspected of having CMV retinitis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A positive CMV antibody is not helpful diagnostically in the acute setting; a negative CMV antibody lowers the diagnostic possibility but does not eliminate CMV infection from consideration. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After an initial period of treatment with anti-CMV therapy and ART, patients may present with visual blurring, floaters, or decreased visual acuity. If this occurs, the patient should be evaluated by an ophthalmologist to determine if these symptoms are related to CMV progression, relapse, or an immune reconstitution inflammatory syndrome, since their clinical management and treatment will differ. (See <a class="local">'CMV in the era of potent combination ART'</a> above and <a class="local">'CMV immune recovery uveitis'</a> above and  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis"</a>.)</p><p></p><p class="headingAnchor" id="H4012766893"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina 2005; 25:633.</a></li><li><a class="nounderline abstract_t">Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329:1922.</a></li><li><a class="nounderline abstract_t">Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223.</a></li><li><a class="nounderline abstract_t">Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213.</a></li><li><a class="nounderline abstract_t">Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002; 133:48.</a></li><li><a class="nounderline abstract_t">Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996; 114:821.</a></li><li><a class="nounderline abstract_t">Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491.</a></li><li><a class="nounderline abstract_t">Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008; 145:397.</a></li><li><a class="nounderline abstract_t">Yust I, Fox Z, Burke M, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23:550.</a></li><li><a class="nounderline abstract_t">Sugar EA, Jabs DA, Ahuja A, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2012; 153:1016.</a></li><li><a class="nounderline abstract_t">Schwarcz L, Chen MJ, Vittinghoff E, et al. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013; 27:597.</a></li><li><a class="nounderline abstract_t">Caplan MR, Wilson EMP, Schechter M, et al. High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era. J Virus Erad 2021; 7:100052.</a></li><li><a class="nounderline abstract_t">Huang Y, Guo X, Song Q, et al. Cytomegalovirus Shedding in Healthy Seropositive Female College Students: A 6-Month Longitudinal Study. J Infect Dis 2018; 217:1069.</a></li><li><a class="nounderline abstract_t">Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.</a></li><li><a class="nounderline abstract_t">Pathanapitoon K, Ausayakhun S, Kunavisarut P, et al. Blindness and low vision in a tertiary ophthalmologic center in Thailand: the importance of cytomegalovirus retinitis. Retina 2007; 27:635.</a></li><li><a class="nounderline abstract_t">Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis 2013; 57:1351.</a></li><li><a class="nounderline abstract_t">Sittivarakul W, Seepongphun U. Incidence Rates and Risk Factors for Vision Loss among AIDS-Related Cytomegalovirus Retinitis Patients in Southern Thailand. Ocul Immunol Inflamm 2018; 26:82.</a></li><li><a class="nounderline abstract_t">Ocieczek P, Barnacle JR, Gumulira J, et al. Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study. Open Forum Infect Dis 2019; 6:ofz439.</a></li><li><a class="nounderline abstract_t">Jay Narain S, Visser L, Sibanda W. Cytomegalovirus retinitis and antiretroviral treatment: A fifteen year experience. South Afr J HIV Med 2022; 23:1322.</a></li><li><a class="nounderline abstract_t">Ei WLSS, Pyar Soe K, Hilbig A, et al. Routine Immediate Eye Examination at the Point of Care for Diagnosis of AIDS-Related Cytomegalovirus Retinitis Among Patients With a CD4 Count &lt;100 in Myanmar. Open Forum Infect Dis 2019; 6:ofz280.</a></li><li class="breakAll">Zumdio AGG, NA Tamayo, LM, A. AIDS Related Cytomegalovirus Screening and Treatment in a Referral Primary Health Centre in Mozambique, Abstract TUPEB056; Presented at the 20th International Conference on AIDS and STDs in Africa, Kigali, 2019.</li><li><a class="nounderline abstract_t">Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443.</a></li><li><a class="nounderline abstract_t">Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285.</a></li><li><a class="nounderline abstract_t">Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14:1163.</a></li><li><a class="nounderline abstract_t">Roels P. Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART). Optometry 2004; 75:624.</a></li><li><a class="nounderline abstract_t">Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003; 121:466.</a></li><li><a class="nounderline abstract_t">Holbrook JT, Jabs DA, Weinberg DV, et al. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol 2003; 121:99.</a></li><li><a class="nounderline abstract_t">Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 2004; 111:2224.</a></li><li><a class="nounderline abstract_t">Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006; 113:684.</a></li><li><a class="nounderline abstract_t">Kempen JH, Jabs DA, Wilson LA, et al. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol 2005; 139:1028.</a></li><li><a class="nounderline abstract_t">Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology 2004; 111:2232.</a></li><li><a class="nounderline abstract_t">Jabs DA, Holbrook JT, Van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005; 112:771.</a></li><li><a class="nounderline abstract_t">Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000; 283:653.</a></li><li><a class="nounderline abstract_t">Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 2005; 6:136.</a></li><li><a class="nounderline abstract_t">Jacobson MA, Maecker HT, Orr PL, et al. Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis 2004; 189:1362.</a></li><li><a class="nounderline abstract_t">Weinberg A, Tierney C, Kendall MA, et al. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J Infect Dis 2006; 193:488.</a></li><li><a class="nounderline abstract_t">Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682.</a></li><li><a class="nounderline abstract_t">Keane NM, Price P, Lee S, et al. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med 2004; 5:407.</a></li><li><a class="nounderline abstract_t">Sinclair E, Tan QX, Sharp M, et al. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J Infect Dis 2006; 194:1537.</a></li><li><a class="nounderline abstract_t">Jacobson MA, Tan QX, Girling V, et al. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis 2008; 46:458.</a></li><li><a class="nounderline abstract_t">Rook AH, Manischewitz JF, Frederick WR, et al. Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. J Infect Dis 1985; 152:627.</a></li><li><a class="nounderline abstract_t">Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038.</a></li><li><a class="nounderline abstract_t">Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. J Clin Invest 1995; 95:1741.</a></li><li><a class="nounderline abstract_t">Bronke C, Palmer NM, Jansen CA, et al. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005; 191:873.</a></li><li><a class="nounderline abstract_t">Weinberg A, Bosch R, Bennett K, et al. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. J Acquir Immune Defic Syndr 2014; 66:25.</a></li><li><a class="nounderline abstract_t">Sezgin E, Jabs DA, Hendrickson SL, et al. Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS. J Infect Dis 2010; 202:606.</a></li><li class="breakAll">Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Ocular Infection and Immunity, Pepose JS, Holland GN, Wilhelmus KR (Eds), CV Mosby, St. Louis 1996. p.1088.</li><li><a class="nounderline abstract_t">Spector SA, Hsia K, Crager M, et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999; 73:7027.</a></li><li><a class="nounderline abstract_t">Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998; 101:497.</a></li><li><a class="nounderline abstract_t">Wohl DA, Kendall MA, Andersen J, et al. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials 2009; 10:143.</a></li><li><a class="nounderline abstract_t">Hodge WG, Boivin JF, Shapiro SH, et al. Iatrogenic risk factors for cytomegalovirus retinitis. Can J Ophthalmol 2005; 40:701.</a></li><li><a class="nounderline abstract_t">Hodge WG, Boivin JF, Shapiro SH, et al. Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology 2004; 111:1326.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on March 04, 2016).</li><li><a class="nounderline abstract_t">Holland GN, Vaudaux JD, Jeng SM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). Am J Ophthalmol 2008; 145:5.</a></li><li><a class="nounderline abstract_t">Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 1989; 107:1759.</a></li><li><a class="nounderline abstract_t">You YS, Lee SJ, Lee SH, et al. Progressive outer retinal necrosis combined with vitreous hemorrhage in a patient with acquired immunodeficiency syndrome. Korean J Ophthalmol 2007; 21:51.</a></li><li><a class="nounderline abstract_t">Sfeir M. Cytomegalovirus implicated in a case of progressive outer retinal necrosis (PORN). J Clin Virol 2015; 69:86.</a></li><li><a class="nounderline abstract_t">Turno-Kręcicka A, Tomczyk-Socha M, Zimny A. Progressive outer retinal necrosis syndrome in the course of systemic lupus erythematosus. Lupus 2016; 25:1610.</a></li><li><a class="nounderline abstract_t">Coisy S, Ebran JM, Milea D. Progressive outer retinal necrosis and immunosuppressive therapy in myasthenia gravis. Case Rep Ophthalmol 2014; 5:132.</a></li><li><a class="nounderline abstract_t">Engstrom RE Jr, Holland GN, Margolis TP, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994; 101:1488.</a></li><li><a class="nounderline abstract_t">Knox CM, Chandler D, Short GA, Margolis TP. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas. Ophthalmology 1998; 105:37.</a></li><li><a class="nounderline abstract_t">Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 1997; 176:50.</a></li><li><a class="nounderline abstract_t">Jabs DA, Gilpin AM, Min YI, et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS 2002; 16:877.</a></li><li><a class="nounderline abstract_t">Goldberg DE, Wang H, Azen SP, Freeman WR. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 2003; 87:853.</a></li><li><a class="nounderline abstract_t">Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm 1999; 7:215.</a></li><li><a class="nounderline abstract_t">Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129:634.</a></li><li><a class="nounderline abstract_t">Thorne JE, Jabs DA, Kempen JH, et al. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 2006; 113:1441.</a></li><li><a class="nounderline abstract_t">Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006; 26:165.</a></li><li><a class="nounderline abstract_t">Robinson MR, Csaky KG, Lee SS, et al. Fibrovascular changes misdiagnosed as cytomegalovirus retinitis reactivation in a patient with immune recovery. Clin Infect Dis 2004; 38:139.</a></li><li><a class="nounderline abstract_t">Karavellas MP, Azen SP, MacDonald JC, et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21:1.</a></li><li><a class="nounderline abstract_t">Raina J, Bainbridge JW, Shah SM. Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS. Eye (Lond) 2000; 14 ( Pt 1):8.</a></li><li><a class="nounderline abstract_t">Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125:292.</a></li><li><a class="nounderline abstract_t">Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999; 83:540.</a></li><li><a class="nounderline abstract_t">Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179:697.</a></li><li><a class="nounderline abstract_t">Wright ME, Suzman DL, Csaky KG, et al. Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin Infect Dis 2003; 36:1063.</a></li><li><a class="nounderline abstract_t">Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 2003; 23:495.</a></li><li><a class="nounderline abstract_t">Song MK, Azen SP, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:696.</a></li></ol></div><div id="topicVersionRevision">Topic 3746 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077362" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : HIV-associated retinopathy in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902536" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1358986" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1345799" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8660165" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618603" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282490" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : AIDS and ophthalmology: the first quarter century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232720" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310076" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34557308" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29294037" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytomegalovirus Shedding in Healthy Seropositive Female College Students: A 6-Month Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18052600" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558328" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Blindness and low vision in a tertiary ophthalmologic center in Thailand: the importance of cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899681" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323489" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence Rates and Risk Factors for Vision Loss among AIDS-Related Cytomegalovirus Retinitis Patients in Southern Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723570" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35399749" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cytomegalovirus retinitis and antiretroviral treatment: A fifteen year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31304189" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Routine Immediate Eye Examination at the Point of Care for Diagnosis of AIDS-Related Cytomegalovirus Retinitis Among Patients With a CD4 Count&lt;100 in Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31304189" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Routine Immediate Eye Examination at the Point of Care for Diagnosis of AIDS-Related Cytomegalovirus Retinitis Among Patients With a CD4 Count&lt;100 in Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164318" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11262214" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894280" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15508863" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695243" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12523893" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582078" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581429" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953432" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582079" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15878056" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665706" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192248" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073672" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425127" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734884" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15544692" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083038" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173357" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2993445" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675046" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706482" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15717261" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24378728" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20617924" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20617924" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400803" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435323" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632953" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518896" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Iatrogenic risk factors for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234132" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical risk factors for cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234132" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical risk factors for cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154750" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556989" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460434" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Progressive outer retinal necrosis combined with vitreous hemorrhage in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209386" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cytomegalovirus implicated in a case of progressive outer retinal necrosis (PORN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27178013" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Progressive outer retinal necrosis syndrome in the course of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24926266" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Progressive outer retinal necrosis and immunosuppressive therapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090452" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9442777" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207349" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919489" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12812884" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10611730" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Immune recovery uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844056" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781775" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467672" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679460" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fibrovascular changes misdiagnosed as cytomegalovirus retinitis reactivation in a patient with immune recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11217922" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755092" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9512145" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216051" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of immune recovery vitritis with local steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9952380" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684920" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972761" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516810" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
